Hodgkin lymphoma outcomes in the novel agent era, genomic safe harbors for precision T cell engineering, and a transcriptomic atlas to map imatinib resistance in CML
Blood Podcast
00:00
The Role of Epigenetic Programming in TKI Resistance
BCR-able tyrosine kinase inhibitors, or TKIs, have been enormously successful in the treatment of CML. Only about 40% of patients achieve a major molecular response after 12 months of treatment. 10 to 15% of patients ultimately progress to blast crisis. There is a need for biomarkers to predict TKI response, thereby setting the stage for novel strategies that can overcome primary resistance.
Transcript
Play full episode
